A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.

Trial Details

NCT ID
NCT06188520
Phase
PHASE1 / PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • AZD8421
  • Camizestrant
  • Ribociclib
  • Palbociclib
  • Abemaciclib
Locations (sample)
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Providence, Rhode Island, United States|41.82399,-71.41283
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Houston, Texas, United States|29.76328,-95.36327
  • East Melbourne, Australia|-37.81667,144.9879

Key Eligibility Criteria

  • Female participants only, aged 18 or above
  • Participants with advanced solid tumors must have received prior adequate therapy in accordance with local practice for their tumor type and stage …
  • Metastatic or locoregionally recurrent disease and radiological or objective evidence of progression on or after the last systemic therapy prior to…
  • ECOG/WHO performance status 0 to 1, and a minimum life expectancy of 12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →